GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Johnson & Johnson (WBO:JNJ) » Definitions » Loans Receivable

Johnson & Johnson (WBO:JNJ) Loans Receivable : €0 Mil (As of Sep. 2024)


View and export this data going back to 2017. Start your Free Trial

What is Johnson & Johnson Loans Receivable?

Johnson & Johnson's Loans Receivable for the quarter that ended in Sep. 2024 was €0 Mil.


Johnson & Johnson Loans Receivable Historical Data

The historical data trend for Johnson & Johnson's Loans Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Johnson & Johnson Loans Receivable Chart

Johnson & Johnson Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Loans Receivable
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Johnson & Johnson Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Loans Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Johnson & Johnson Loans Receivable Calculation

Loans Receivable are the funds that a company has lent but have not yet been repaid.


Johnson & Johnson Loans Receivable Related Terms

Thank you for viewing the detailed overview of Johnson & Johnson's Loans Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.


Johnson & Johnson Business Description

Address
One Johnson and Johnson Plaza, New Brunswick, NJ, USA, 08933
Johnson & Johnson is the world's largest and most diverse healthcare firm. It has two divisions: pharmaceutical and medical devices. These now represent all of the company's sales following the divestment of the consumer business, Kenvue, in 2023. The drug division focuses on the following therapeutic areas: immunology, oncology, neurology, pulmonary, cardiology, and metabolic diseases. Geographically, just over half of total revenue is generated in the United States.